Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Schwartz

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 19, 2006
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreasJohn C Mansour, Lawrence Schwartz, Neeta Pandit-Taskar, et al.
Investigational New Drugs|July 13, 2006
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancerNancy Kemeny, William Jarnagin, Philip Paty, et al.
Urology|May 29, 2002
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris, Timothy Akhurst, Iman Osman, et al.
Investigational New Drugs|January 24, 2004
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, et al.
Cancer|October 30, 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaDavid B Solit, Michael Morris, Susan Slovin, et al.
Academic Radiology|December 9, 2009
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarkerAndrew J Buckler, P David Mozley, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Oncology|June 17, 2011
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?Nancy E Kemeny, Lawrence Schwartz, Mithat Gönen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancerWilliam Kevin Kelly, Andrew X Zhu, Howard Scher, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 19, 2006
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreasJohn C Mansour, Lawrence Schwartz, Neeta Pandit-Taskar, et al.
Investigational New Drugs|July 13, 2006
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaEllen A Ronnen, G Varuni Kondagunta, Nicole Ishill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancerNancy Kemeny, William Jarnagin, Philip Paty, et al.
Urology|May 29, 2002
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris, Timothy Akhurst, Iman Osman, et al.
Investigational New Drugs|January 24, 2004
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumorsG Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, et al.
Cancer|October 30, 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaDavid B Solit, Michael Morris, Susan Slovin, et al.
Academic Radiology|December 9, 2009
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarkerAndrew J Buckler, P David Mozley, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Oncology|June 17, 2011
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?Nancy E Kemeny, Lawrence Schwartz, Mithat Gönen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancerWilliam Kevin Kelly, Andrew X Zhu, Howard Scher, et al.
Pageof 9